Baker Bros. Advisors LP Uni Qure N.V. Transaction History

Baker Bros. Advisors LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$29.24 - $42.03 $197,077 - $283,282	-6,740 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$35.35 - $50.67 $6.63 Million - $9.51 Million	-187,643 Reduced 96.53%	6,740 $244,000
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $1.31 Million - $1.74 Million	-36,500 Reduced 15.81%	194,383 $7.16 Million
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $5.69 Million - $8.55 Million	-126,200 Reduced 35.34%	230,883 $10.4 Million
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $6.43 Million - $11.9 Million	-160,617 Reduced 31.03%	357,083 $16.9 Million
Q2 2019 Aug 14, 2019	SELL	$52.76 - $82.19 $4.61 Million - $7.18 Million	-87,300 Reduced 14.43%	517,700 $40.5 Million
Q2 2018 Aug 14, 2018	BUY	$21.96 - $39.94 $2.31 Million - $4.19 Million	105,000 Added 21.0%	605,000 $22.9 Million
Q1 2018 May 15, 2018	BUY	$17.1 - $26.61 $298,275 - $464,158	17,443 Added 3.61%	500,000 $11.8 Million
Q4 2017 Feb 14, 2018	BUY	$9.47 - $19.59 $4.57 Million - $9.45 Million	482,557	482,557 $9.45 Million

141

33.7M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $237M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.